Phase III randomised controlled trials (RCTs) are usually analysed and published according to a statistical plan, when the number of events is expected be sufficient establish (at P < 0.05) or exclude (with power 80% 90%) prespecified difference in primary time-to-event outcome. For that evaluate treatments for metastatic cancer, end point most often overall survival (OS) progression-free (PFS)...